An unusually impressive atorvastatin-induced elevation of serum alkaline phosphatase. Issue 2 (10th February 2020)

• Record Type: Journal Article
• Authors: Chapman, George; Tanner, Stephanie
• Is Part Of: BMJ case reports. Volume 13:Issue 2(2020)
• Publication Date: 2020-02-10
• Subjects: drug interactions -- contraindications and precautions -- drugs: gastrointestinal system -- liver disease -- unwanted effects / adverse reactions; Medicine -- Case studies -- Periodicals; 610.5
• DOI: 10.1136/bcr-2019-231839
• Languages: English
• ISSNs: 1757-790X

Abstract

Abstract : A 90-year-old woman is referred six months after a transient ischaemic attack (TIA) with asymptomatic cholestatic liver function test (LFT) derangement. Following the TIA, atorvastatin and clopidogrel therapy are initiated. This is added to pre-existent once daily nifedipine for hypertension. Nifedipine (a weak inhibitor of CYP3A4 and competing substrate) and clopidogrel (a competitive inhibitor of CYP3A4) may have affected the metabolism of atorvastatin, resulting in the elevation of serum alkaline phosphatase levels to over six times the upper limit of normal. More often, statin therapy elevates serum alanine aminotransferase levels. Drug-induced liver injury (DILI) was deemed 'probable' as judged by the Roussel Uclaf Causality Assessment Method score. Statin therapy remains overwhelmingly safe, with benefits outweighing risks in the vast majority. The UK recommended LFT monitoring regime facilitates early recognition of DILI. Case reports are examined where similar drug combinations resulted in severe morbidity and mortality.